JP5490696B2 - インフルエンザウイルスｈ５亜型またはｎ１亜型からのヘマグルチニンおよびノイラミニダーゼに特異的なモノクローナル抗体ならびにそれらの使用 - Google Patents

インフルエンザウイルスｈ５亜型またはｎ１亜型からのヘマグルチニンおよびノイラミニダーゼに特異的なモノクローナル抗体ならびにそれらの使用 Download PDF

Info

Publication number
JP5490696B2
JP5490696B2 JP2010524824A JP2010524824A JP5490696B2 JP 5490696 B2 JP5490696 B2 JP 5490696B2 JP 2010524824 A JP2010524824 A JP 2010524824A JP 2010524824 A JP2010524824 A JP 2010524824A JP 5490696 B2 JP5490696 B2 JP 5490696B2
Authority
JP
Japan
Prior art keywords
antibody
mab
binding protein
subtype
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010524824A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010539162A (ja
JP2010539162A5 (enExample
Inventor
チャン，ホン・リャン
ヘ，ファン
クァン，ウェイ−シン
Original Assignee
テマセック・ライフ・サイエンシズ・ラボラトリー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テマセック・ライフ・サイエンシズ・ラボラトリー・リミテッド filed Critical テマセック・ライフ・サイエンシズ・ラボラトリー・リミテッド
Publication of JP2010539162A publication Critical patent/JP2010539162A/ja
Publication of JP2010539162A5 publication Critical patent/JP2010539162A5/ja
Application granted granted Critical
Publication of JP5490696B2 publication Critical patent/JP5490696B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C07K16/108—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2010524824A 2007-09-13 2008-09-12 インフルエンザウイルスｈ５亜型またはｎ１亜型からのヘマグルチニンおよびノイラミニダーゼに特異的なモノクローナル抗体ならびにそれらの使用 Expired - Fee Related JP5490696B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97205907P 2007-09-13 2007-09-13
US60/972,059 2007-09-13
PCT/SG2008/000347 WO2009035420A1 (en) 2007-09-13 2008-09-12 Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus h5-subtype or n1-subtype and uses thereof

Publications (3)

Publication Number Publication Date
JP2010539162A JP2010539162A (ja) 2010-12-16
JP2010539162A5 JP2010539162A5 (enExample) 2012-08-16
JP5490696B2 true JP5490696B2 (ja) 2014-05-14

Family

ID=40452269

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010524824A Expired - Fee Related JP5490696B2 (ja) 2007-09-13 2008-09-12 インフルエンザウイルスｈ５亜型またはｎ１亜型からのヘマグルチニンおよびノイラミニダーゼに特異的なモノクローナル抗体ならびにそれらの使用

Country Status (7)

Country Link
US (3) US8383121B2 (enExample)
EP (2) EP2947094B1 (enExample)
JP (1) JP5490696B2 (enExample)
CN (2) CN101883789B (enExample)
AU (1) AU2008297594B2 (enExample)
SG (2) SG183031A1 (enExample)
WO (1) WO2009035420A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2155787A4 (en) * 2007-05-11 2010-06-16 Temasek Life Sciences Lab Ltd SPECIFIC TO THE H5-SUBTYPE BINDING PROTEINS SUITED TO THE DIAGNOSIS AND MONITORING OF THE H5 BIRGRAP
EP2265947A4 (en) * 2008-03-20 2011-03-30 Abay Sa MULTI-LENGTH WAVE LENGTH ANALYSIS OF SOL-PARTICULATE SPECIFIC BINDING TESTS
AU2010247530B2 (en) * 2009-05-11 2016-10-13 Janssen Vaccines & Prevention B.V. Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof
CN102869379B (zh) * 2010-04-30 2015-04-15 淡马锡生命科学研究院有限公司 H5n1谱系的通用疫苗
WO2012054745A1 (en) * 2010-10-20 2012-04-26 New York Blood Center, Inc. Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection
JP2013087069A (ja) * 2011-10-17 2013-05-13 Toyobo Co Ltd Ｈ５亜型インフルエンザウイルスを特異的に認識するモノクローナル抗体
WO2013105896A1 (en) * 2012-01-12 2013-07-18 Temasek Life Sciences Laboratory Limited Monoclonal antibodies targeting neutralizing epitopes on h5 influenza virus of clade 2.3
TW201346040A (zh) * 2012-03-30 2013-11-16 田中貴金屬工業股份有限公司 流行性感冒ａ型病毒檢驗用套組
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
SG11201503878XA (en) * 2012-11-19 2015-06-29 Temasek Life Sciences Lab Ltd Monoclonal antibodies targeting neutralizing epitopes on h7 influenza viruses
CN104407133A (zh) * 2014-11-03 2015-03-11 清华大学深圳研究生院 A型流感病毒检测方法及其试剂盒
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
WO2017083627A1 (en) 2015-11-13 2017-05-18 Visterra, Inc. Compositions and methods for treating and preventing influenza
US20170240617A1 (en) 2016-02-24 2017-08-24 Visterra, Inc. Formulations of antibody molecules to influenza virus
PL238020B1 (pl) 2016-09-12 2021-06-28 Inst Biotechnologii I Antybiotykow Kompozycja przeciwciał monoklonalnych przeciwko hemaglutyninie wirusów grypy serotypu H5 i jej zastosowanie, hybrydomy produkujące rzeczone przeciwciała, sposób diagnozowania infekcji wirusami grypy serotypu H5 oraz zestawy diagnostyczne
CN106399265B (zh) * 2016-09-19 2018-03-02 中国动物卫生与流行病学中心 一种提高禽流感疫苗毒株增殖滴度的方法
CA3088194A1 (en) 2018-01-26 2019-08-01 Regeneron Pharmaceuticals, Inc. Human antibodies to influenza hemagglutinin
US11230593B2 (en) 2019-03-25 2022-01-25 Visterra, Inc. Compositions and methods for treating and preventing influenza
CN110483637B (zh) * 2019-07-22 2022-06-10 扬州大学 一种抗禽流感病毒神经氨酸酶n2单克隆抗体、编码基因及其应用
CN112574297B (zh) * 2019-09-27 2022-06-24 上海生物制品研究所有限责任公司 抗神经氨酸酶的单克隆抗体及其应用
WO2021201677A1 (en) 2020-04-01 2021-10-07 Kiadis Pharma Intellectual Property B.V. Compositions and methods targeting influenza
JP2023551667A (ja) * 2020-11-23 2023-12-12 ヴィア・バイオテクノロジー・インコーポレイテッド 抗－インフルエンザ抗体及びその組合せ
KR102605065B1 (ko) * 2021-10-14 2023-11-22 원광대학교산학협력단 고병원성 조류 인플루엔자 바이러스 h5n1에 특이적인 단클론항체 및 이를 이용한 신속 진단 키트

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP5525688B2 (ja) 2005-08-19 2014-06-18 株式会社ビーエル インフルエンザウイルスｈ５亜型の免疫検出法
EP1928914A2 (en) 2005-09-15 2008-06-11 Crucell Holland B.V. Method for preparing immunoglobulin libraries
JP2009524434A (ja) * 2006-01-26 2009-07-02 エイチエックス・ダイアグノスティックス・インコーポレイテッド トリインフルエンザウイルス亜型ｈ５ヘマグルチニンに結合するモノクローナル抗体およびそれらの使用
US8192927B2 (en) 2006-09-07 2012-06-05 Crucell Holland B.V. Human bind molecules capable of neutralizing influenza virus h5n1 and uses thereof
EP2155787A4 (en) * 2007-05-11 2010-06-16 Temasek Life Sciences Lab Ltd SPECIFIC TO THE H5-SUBTYPE BINDING PROTEINS SUITED TO THE DIAGNOSIS AND MONITORING OF THE H5 BIRGRAP
US7879326B2 (en) * 2007-06-15 2011-02-01 The Board Of Trustees Of The Leland Stanford Junior University Human neutralizing monoclonal antibodies to H5N1 influenza A virus
WO2009035412A1 (en) * 2007-09-13 2009-03-19 Temasek Life Sciences Laboratory Limited Monoclonal antibodies specific to hemagglutinin from influenza virus h5-subtype and uses thereof

Also Published As

Publication number Publication date
AU2008297594A1 (en) 2009-03-19
AU2008297594B2 (en) 2013-06-20
EP2201039A1 (en) 2010-06-30
US20130004496A1 (en) 2013-01-03
CN103214570B (zh) 2014-12-10
SG183032A1 (en) 2012-08-30
US8540996B2 (en) 2013-09-24
WO2009035420A1 (en) 2009-03-19
EP2947094A1 (en) 2015-11-25
EP2201039A4 (en) 2012-04-11
CN101883789B (zh) 2014-10-08
US8574581B2 (en) 2013-11-05
US20100266585A1 (en) 2010-10-21
JP2010539162A (ja) 2010-12-16
EP2947094B1 (en) 2018-11-14
WO2009035420A8 (en) 2009-05-07
EP2201039B1 (en) 2015-07-15
SG183031A1 (en) 2012-08-30
CN101883789A (zh) 2010-11-10
CN103214570A (zh) 2013-07-24
US8383121B2 (en) 2013-02-26
US20130004497A1 (en) 2013-01-03

Similar Documents

Publication Publication Date Title
JP5490696B2 (ja) インフルエンザウイルスｈ５亜型またはｎ１亜型からのヘマグルチニンおよびノイラミニダーゼに特異的なモノクローナル抗体ならびにそれらの使用
JP5490695B2 (ja) インフルエンザウイルスｈ５亜型からのヘマグルチニンに特異的なモノクローナル抗体およびそれらの使用
JP5597128B2 (ja) Ｈ５トリインフルエンザの診断および監視に有用なｈ５亜型特異的結合タンパク質
AU2013224734A1 (en) Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus h5-subtype or n1-subtype and uses thereof
HK1161725B (en) H5 subtype-specific binding proteins useful for h5 avian influenza diagnosis and surveillance
CN102718863A (zh) 可用于h5禽流感诊断和监视的h5亚型特异性结合蛋白

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110829

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120627

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130430

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130801

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131227

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140128

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140226

R150 Certificate of patent or registration of utility model

Ref document number: 5490696

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees